Evidence map›Paper›PMID 36709178›Full record

GuidelineZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2022

[Chinese guideline for diagnosis and treatment of transfusion dependent β-thalassemia (2022)].

Red Blood Cell Diseases (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association

Abstract readPractice Guideline
In one paragraph

Guideline in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. [Guideline for transfusion management in Chinese children with transfusion-dependent thalassemia (2025)].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Guideline
  2. [Guidelines for iron chelation therapy in thalassemia in China (2025)].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Guideline
  3. Article
  4. Article
  5. Article
  6. Article
  7. Preclinical efficacy and safety evaluation of BD211 autologous CD34Frontiers in cell and developmental biology · 2025
    Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Red Blood Cell Diseases (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

beta-ThalassemiaBlood TransfusionHumans

Identifiers

PMID36709178
PMCPMC9808868

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.